16:20 EDT Dermata Therapeutics (DRMA) files to sell 10.01M shares of common stock for holders
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRMA:
- Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks
- Buy Rating for Dermata Therapeutics: Promising Phase 3 Results and Strategic Advantages
- Dermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpoints
- Dermata Therapeutics announces last patient visit in Phase 3 acne trial
- Dermata Therapeutics receives notice of acceptance for Australian patent
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue